TNDM241115P19000
- 0.00
- 0.000.00%
Tandem Diabetes Care Newsroom
Morgan Stanley Maintains Tandem Diabetes Care(TNDM.US) With Hold Rating, Maintains Target Price $45
Analysts Have Conflicting Sentiments on These Healthcare Companies: Waters (WAT), Pharvaris (PHVS) and Tandem Diabetes Care (TNDM)
Assessing MedTech Impact From Potential China Tariffs
Barclays Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Raises Target Price to $60
A Quick Look at Today's Ratings for Tandem Diabetes Care(TNDM.US), With a Forecast Between $40 to $75
Here's What Analysts Are Forecasting For Tandem Diabetes Care, Inc. (NASDAQ:TNDM) After Its Third-Quarter Results
Tandem Diabetes Care Is Maintained at Buy by Canaccord Genuity
Baird Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $37
Tandem Diabetes Care Analyst Ratings
A Quick Look at Today's Ratings for Tandem Diabetes Care(TNDM.US), With a Forecast Between $37 to $65
RBC Capital Remains a Buy on Tandem Diabetes Care (TNDM)
Express News | Tandem Diabetes Care Inc : Leerink Partners Cuts Target Price to $59 From $62
Tandem Diabetes Care, Inc. (TNDM) Q3 2024 Earnings Conference Call Transcript Summary
Tandem Diabetes Care, Inc. (TNDM) Q3 2024 Earnings Conference Call Transcript
Tandem Diabetes Care, Inc. (TNDM) Reports Q3 Loss, Tops Revenue Estimates
Tandem Diabetes Care | 10-Q: Q3 2024 Earnings Report
Earnings Flash (TNDM) TANDEM DIABETES CARE Posts Q3 Revenue $244M
Express News | Tandem Diabetes Care Outlook FY Adjusted Sales USD 903-910 Million
Express News | Tandem Diabetes Care Q3 Adjusted Net Income USD -23.6 Million Vs. IBES Estimate USD -28 Million
Press Release: Tandem Diabetes Care Announces Third Quarter 2024 Financial Results and Increases Full Year 2024 Sales Guidance